Riskpilot← Back to searchSign inGet full accessLUNGEPRAKSIS AS
ASActiveOrg 993779148Tåsenveien 85C, 0873 OsloMedical specialists activities · NACE 8622Est. 20091 employees
Revenue 2023
NOK 508K
-41% vs 2022
EBITDA margin
47.7%
-56% vs 2022
Equity ratio
17.4%
Financial strength
Net profit 2023
NOK 27K
-91% vs 2022
| Revenue | NOK 508K | -41% |
| EBITDA | NOK 242K | -56% |
| Net profit | NOK 27K | -91% |
| Total assets | NOK 1M | -26% |
| Equity | NOK 182K | -53% |
| Employees | 1 | — |
Legal name
LUNGEPRAKSIS AS
Org number
993779148
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
12. mars 2009
Share capital
NOK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Spesialistpraksis i lungemedisin og indremedisin. Kjøp og salg av verdipapirer, eiendommer og alt hva herved kommer i forbindelse.
Address
Tåsenveien 85C, 0873 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 1 538 | 1 698 | 1 690 | 863 | 508 |
| Staff expenses | −1 | −17 | −20 | −26 | −24 |
| EBITDA | 1 354 | 1 477 | 1 478 | 546 | 242 |
| Depreciation & amort. | −0 | −150 | −180 | −180 | −190 |
| EBIT | 1 354 | 1 327 | 1 298 | 366 | 52 |
| Net financials | −10 | −6 | −4 | −3 | −18 |
| Profit before tax | 1 345 | 1 321 | 1 294 | 362 | 34 |
| Tax | 296 | 291 | 285 | 80 | 7 |
| Net profit | 1 049 | 1 030 | 1 009 | 283 | 27 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 2 312 | 2 525 | 1 904 | 1 406 | 1 047 |
| Equity | 665 | 196 | 705 | 387 | 182 |
| Long-term debt | 0 | 503 | 382 | 276 | 0 |
| Short-term debt | 1 647 | 1 826 | 816 | 743 | 865 |
| Total debt | 1 647 | 2 329 | 1 199 | 1 019 | 865 |
EBITDA margin
47.7%
This company
15.8%
Market median
+202% vs market
20192023
Equity ratio
17.4%
This company
38.2%
Market median
-54% vs market
20192023
Return on equity
14.6%
This company
18.4%
Market median
+21% vs market
20192023
Net profit margin
5.2%
This company
8.1%
Market median
-36% vs market
20192023
Asset turnover
0.49×
This company
1.12×
Market median
-56% vs market
20192023
Debt / equity
4.76×
This company
0.62×
Market median
-668% vs market
20192023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GH Deputy Member | Deputy Member | 2009 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2009 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LUNGEPRAKSIS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Greetje Henriette Refvem | Deputy Member | 0 companies |
| Olav Kåre Refvem | Chairman | 0 companies |